Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
GnRH antagonist

Linzagolix

Brand names: Yselty

An orally active gonadotrophin-releasing hormone (GnRH) receptor antagonist used in the management of symptoms associated with uterine fibroids.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It competitively blocks pituitary GnRH receptors, dose-dependently suppressing luteinising hormone and follicle-stimulating hormone release and thereby lowering circulating oestradiol.

Prescribing in practice

  • Because oestrogen suppression reduces bone mineral density, assess bone health and use combined hormonal add-back therapy where indicated, limiting treatment duration accordingly.
  • Exclude pregnancy before starting and ensure effective non-hormonal or appropriate contraception during treatment.
  • Review the SPC for cautions in hepatic impairment and for interactions before prescribing.

Monitoring

Monitor menstrual bleeding response, bone mineral density over prolonged use, and liver-related parameters in line with current prescribing references.

Counselling the patient

  • Menopause-like effects such as hot flushes may occur, particularly without add-back hormone therapy.
  • Do not become pregnant while taking this medicine and use reliable contraception.
  • Attend bone-density and review appointments as arranged.

Evidence & guidelines

Linzagolix was evaluated for heavy menstrual bleeding due to uterine fibroids in the PRIMROSE phase 3 trials.

Reference: NICE TA945; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Drugs
Pathways